Machine learning in preclinical drug discovery.

Area of Science:

• Pharmacology
• Biotechnology
• Computational Chemistry

Background:

• Drug discovery is a lengthy, expensive process with a high failure rate.
• Traditional drug development faces significant challenges in efficiency and cost.
• The increasing availability of large biological and chemical datasets provides opportunities for computational approaches.

Purpose of the Study:

• To discuss the integration of machine learning (ML) methods in preclinical drug discovery.
• To highlight ML applications for accelerating key stages of early drug development.
• To explore the potential of ML to revolutionize drug discovery pipelines.

Main Methods:

• Review of existing machine learning applications in drug discovery.
• Analysis of ML-based efforts across diverse therapeutic areas.
• Discussion of ML's role in hit discovery, MOA elucidation, and property optimization.

Main Results:

• Machine learning techniques are well-positioned to augment traditional drug development.
• ML accelerates initial hit discovery, mechanism-of-action (MOA) elucidation, and chemical property optimization.
• ML-based efforts show promise across various disease areas.

Conclusions:

• Integrating algorithmic methods throughout preclinical drug discovery is crucial.
• Fully ML-integrated drug discovery pipelines are poised to define the future of drug development.
• ML offers a powerful toolkit to enhance the efficiency and success rate of drug discovery programs.